As a fixed-dose combination, CagriSema was assessed in two phase 3 studies (REDEFINE 1 and 2), resulting in significant and clinically relevant reductions in body weight compared with placebo in adults with overweight or obesity, with [8] or without type 2 diabetes [9]
Studied for body-weight reduction Investigated in the phase 3 REDEFINE program for change in body weight in adults with obesity, with and without type 2 diabetes
Depending on the treatment, you'll want to prep the area beforehand by removing any makeup, lotion, sunscreen, deodorant, or product
Major drivers include aging populations, increased hair loss concerns post-COVID-19, and growing consumer awareness
Standard Dosing Range Research protocols typically use 0.25-0.5 mg (250-500 mcg) of BPC-157 daily via subcutaneous injection
Concentration calculations Understanding concentration math ensures accurate dosing throughout your vial's use